




H&E




p16

Copy Number Plot




Case 36
CDKN2A HD






Case 37
CDKN2A HD






Case 39
CDKN2A HD






Case 40
CDKN2A HD



Case 42
CDKN2A HD




Case 43
CDKN2A FS



Supplementary Figure 1. Loss of p16 expression in *CDKN2A*-altered meningiomas. Homozygous deletion (HD), frameshift mutation (FS)

H&E

p16



Supplementary Figure 2. Spectrum of p16 expression in CNS WHO grade 1 meningiomas with intact/wildtype *CDKN2A* alleles. 9/14 tumors (64%) demonstrated minimal to absent p16 immunoreactivity despite absence of *CDKN2A* alterations.